Are oncoantigens suitable targets for anti-tumour therapy? (original) (raw)

• Szabo, E. Selecting targets for cancer prevention: where do we go from here? Nature Rev. Cancer 6, 867–874 (2006).
  Article CAS Google Scholar
• Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nature Rev. Cancer 6, 392–401 (2006).
  Article CAS Google Scholar
• Karre, K., Ljunggren, H. G., Piontek, G. & Kiessling, R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319, 675–678 (1986).
  Article CAS PubMed Google Scholar
• Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727–729 (1999).
  Article CAS PubMed Google Scholar
• Nolte-'t Hoen, E. N. et al. Increased surveillance of cells in mitosis by human NK cells suggests a novel strategy for limiting tumor growth and viral replication. Blood 109, 670–673 (2007).
  Article CAS PubMed Google Scholar
• Merlo, L. M., Pepper, J. W., Reid, B. J. & Maley, C. C. Cancer as an evolutionary and ecological process. Nature Rev. Cancer 6, 924–935 (2006).
  Article CAS Google Scholar
• Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991–998 (2002).
  Article CAS Google Scholar
• Finn, O. J. Premalignant lesions as targets for cancer vaccines. J. Exp. Med. 198, 1623–1626 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Lollini, P. L., Cavallo, F., Nanni, P. & Forni, G. Vaccines for tumour prevention. Nature Rev. Cancer 6, 204–216 (2006).
  Article CAS Google Scholar
• Finn, O. J. Cancer vaccines: between the idea and the reality. Nature Rev. Immunol. 3, 630–641 (2003).
  Article CAS Google Scholar
• Lollini, P. L. & Forni, G. Cancer immunoprevention: tracking down persistent tumor antigens. Trends Immunol. 24, 62–66 (2003).
  Article CAS PubMed Google Scholar
• Nanni, P. et al. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int. J. Cancer 87, 186–194 (2000).
  Article CAS PubMed Google Scholar
• Holmgren, L. et al. A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc. Natl Acad. Sci. USA 103, 9208–9213 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Ferrara, N., Mass, R. D., Campa, C. & Kim, R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu. Rev. Med. 58, 491–504 (2007).
  Article CAS PubMed Google Scholar
• Friedman, L. M. et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc. Natl Acad. Sci. USA 102, 1915–1920 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Nanni, P. et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 194, 1195–1205 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Luo, W., Ko, E., Hsu, J. C., Wang, X. & Ferrone, S. Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J. Immunol. 176, 6046–6054 (2006).
  Article CAS PubMed Google Scholar
• Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2, 127–137 (2001).
  Article CAS Google Scholar
• Boccaccio, C. & Comoglio, P. M. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nature Rev. Cancer 6, 637–645 (2006).
  Article CAS Google Scholar
• Zbuk, K. M. & Eng, C. Cancer phenomics: RET and PTEN as illustrative models. Nature Rev. Cancer 7, 35–45 (2007).
  Article CAS Google Scholar
• Pedersen, I. M., Buhl, A. M., Klausen, P., Geisler, C. H. & Jurlander, J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99, 1314–1319 (2002).
  Article CAS PubMed Google Scholar
• Gunawardana, C. G. & Diamandis, E. P. High throughput proteomic strategies for identifying tumour-associated antigens. Cancer Lett. 249, 110–119 (2007).
  Article CAS PubMed Google Scholar
• Preuss, K. D., Zwick, C., Bormann, C., Neumann, F. & Pfreundschuh, M. Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol. Rev. 188, 43–50 (2002).
  Article CAS PubMed Google Scholar
• Klade, C. S. Proteomics approaches towards antigen discovery and vaccine development. Curr. Opin. Mol. Ther. 4, 216–223 (2002).
  CAS PubMed Google Scholar
• Kreunin, P., Yoo, C., Urquidi, V., Lubman, D. M. & Goodison, S. Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model. Proteomics 7, 299–312 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• He, Y. D. Genomic approach to biomarker identification and its recent applications. Cancer Biomark. 2, 103–133 (2006).
  Article CAS PubMed Google Scholar
• Narayanan, R. Bioinformatics approaches to cancer gene discovery. Methods Mol. Biol. 360, 13–31 (2007).
  CAS PubMed Google Scholar
• Abate-Shen, C. A new generation of mouse models of cancer for translational research. Clin. Cancer Res. 12, 5274–5276 (2006).
  Article CAS PubMed Google Scholar
• Rangarajan, A. & Weinberg, R. A. Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nature Rev. Cancer 3, 952–959 (2003).
  Article CAS Google Scholar
• Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153–158 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Weitzman, J. B. & Yaniv, M. Rebuilding the road to cancer. Nature 400, 401–402 (1999).
  Article CAS PubMed Google Scholar
• Pillai, R. S., Bhattacharyya, S. N. & Filipowicz, W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol. 17, 118–126 (2007).
  Article CAS PubMed Google Scholar
• Hossain, A., Kuo, M. T. & Saunders, G. F. Mir-17–5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol. Cell Biol. 26, 8191–8201 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Uhlen, M. et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell Proteomics 4, 1920–1932 (2005).
  Article CAS PubMed Google Scholar
• Cavallo, F. et al. An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention. BMC Bioinformatics 6 Suppl. 4, S7 (2005).
  Article PubMed PubMed Central CAS Google Scholar
• Barrett, T. et al. NCBI GEO: mining tens of millions of expression profiles--database and tools update. Nucleic Acids Res. 35, D760–D765 (2007).
  Article CAS PubMed Google Scholar
• Parkinson, H. et al. ArrayExpress-a public database of microarray experiments and gene expression profiles. Nucleic Acids Res. 35, D747–D750 (2007).
  Article CAS PubMed Google Scholar
• Michiels, S., Koscielny, S. & Hill, C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365, 488–492 (2005).
  Article CAS PubMed Google Scholar
• Sims, A. H., Ong, K. R., Clarke, R. B. & Howell, A. High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic? Breast Cancer Res. 8, 214 (2006).
  Article PubMed PubMed Central Google Scholar
• Lu, Y. et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med. 3, e467 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• Mehra, R. et al. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 65, 11259–11264 (2005).
  Article CAS PubMed Google Scholar
• Miles, M. F. & Williams, R. W. Meta-analysis for microarray studies of the genetics of complex traits. Trends Biotechnol. 25, 45–47 (2007).
  Article CAS PubMed Google Scholar
• Hyatt, G. et al. Gene expression microarrays: glimpses of the immunological genome. Nature Immunol. 7, 686–691 (2006).
  Article CAS Google Scholar
• van 't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).
  Article CAS PubMed Google Scholar
• Miller, L. D. et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl Acad. Sci. USA 102, 13550–13555 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Pawitan, Y. et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 7, R953–R964 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Calogero, R., Cordero, F, Forni, G & Cavallo, F. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice. Breast Cancer Res. (in the press).
• Vlad, A. M., Kettel, J. C., Alajez, N. M., Carlos, C. A. & Finn, O. J. MUC1 immunobiology: from discovery to clinical applications. Adv. Immunol. 82, 249–293 (2004).
  Article CAS PubMed Google Scholar
• Carraway, K. L., 3rd, Funes, M., Workman, H. C. & Sweeney, C. Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr. Top. Dev. Biol. 78, 1–22 (2007).
  Article CAS PubMed Google Scholar
• Wei, X., Xu, H. & Kufe, D. Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res. 67, 1853–1858 (2007).
  Article CAS PubMed Google Scholar
• Thompson, E. J. et al. Tyrosines in the MUC1 cytoplasmic tail modulate transcription via the extracellular signal-regulated kinase 1/2 and nuclear factor-κB pathways. Mol. Cancer Res. 4, 489–497 (2006).
  Article CAS PubMed Google Scholar
• Singh, P. K. & Hollingsworth, M. A. Cell surface-associated mucins in signal transduction. Trends Cell Biol. 16, 467–476 (2006).
  Article CAS PubMed Google Scholar
• Kohlgraf, K. G. et al. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res. 63, 5011–5020 (2003).
  CAS PubMed Google Scholar
• Ambrosino, E. et al. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res. 66, 7734–7740 (2006).
  Article CAS PubMed Google Scholar
• Rolla, S. et al. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J. Immunol. 177, 7626–7633 (2006).
  Article CAS PubMed Google Scholar
• Sakaguchi, N. et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426, 454–460 (2003).
  Article CAS PubMed Google Scholar
• Disis, M. L. et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol. 15, 3363–3367 (1997).
  Article CAS PubMed Google Scholar
• Al-Batran, S. E. et al. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res. 65, 3937–3941 (2005).
  Article CAS PubMed Google Scholar
• Ohlen, C. et al. CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J. Exp. Med. 195, 1407–1418 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Nanni, P. et al. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J. Immunol. 173, 2288–2296 (2004).
  Article CAS PubMed Google Scholar
• Park, J. M. et al. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J. Immunol. 174, 4228–4236 (2005).
  Article CAS PubMed Google Scholar
• Imai, K. & Takaoka, A. Comparing antibody and small-molecule therapies for cancer. Nature Rev. Cancer 6, 714–727 (2006).
  Article CAS Google Scholar
• Terabe, M. et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198, 1741–1752 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Bronte, V. & Zanovello, P. Regulation of immune responses by L-arginine metabolism. Nature Rev. Immunol. 5, 641–654 (2005).
  Article CAS Google Scholar
• Gallina, G. et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116, 2777–2790 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Lustgarten, J., Dominguez, A. L. & Cuadros, C. The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur. J. Immunol. 34, 752–761 (2004).
  Article CAS PubMed Google Scholar
• Cavallo, F., Offringa, R., van der Burg, S. H., Forni, G. & Melief, C. J. Vaccination for treatment and prevention of cancer in animal models. Adv. Immunol. 90, 175–213 (2006).
  Article CAS PubMed Google Scholar
• Quaglino, E. et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res. 64, 2858–2864 (2004).
  Article CAS PubMed Google Scholar
• Quaglino, E. et al. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J. Clin. Invest. 113, 709–717 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Haber, D. A. & Settleman, J. Cancer: drivers and passengers. Nature 446, 145–146 (2007).
  Article CAS PubMed Google Scholar
• Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268–274 (2006).
  Article CAS PubMed Google Scholar
• Pannellini, T. et al. Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. J. Immunol. 176, 7695–7703 (2006).
  Article CAS PubMed Google Scholar
• Dorrell, M. I., Aguilar, E., Scheppke, L., Barnett, F. H. & Friedlander, M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc. Natl Acad. Sci. USA 104, 967–972 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Emens, L. A. Roadmap to a better therapeutic tumor vaccine. Int. Rev. Immunol. 25, 415–443 (2006).
  Article CAS PubMed Google Scholar
• Lu, H., Knutson, K. L., Gad, E. & Disis, M. L. The tumor antigen repertoire identified in tumor-bearing Neu transgenic mice predicts human tumor antigens. Cancer Res. 66, 9754–9761 (2006).
  Article CAS PubMed Google Scholar
• Pannellini, T., Forni, G. & Musiani, P. Immunobiology of her-2/neu transgenic mice. Breast Dis. 20, 33–42 (2004).
  Article PubMed Google Scholar
• Astolfi, A. et al. Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. Am. J. Pathol. 166, 1205–1216 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Astolfi, A. et al. Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. Cancer Immunol. Immunother. 54, 599–610 (2005).
  Article CAS PubMed Google Scholar
• Melani, C., Chiodoni, C., Forni, G. & Colombo, M. P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102, 2138–2145 (2003).
  Article CAS PubMed Google Scholar
• Garber, K. New insights into oncogene addiction found. J. Natl Cancer Inst. 99, 264–265, 269 (2007).
  Article PubMed Google Scholar
• Cappello, P. et al. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res. 63, 2518–25 (2003).
  CAS PubMed Google Scholar
• Ercolini, A. M. et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 201, 1591–1602 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Albini, A. & Sporn, M. B. The tumour microenvironment as a target for chemoprevention. Nature Rev. Cancer 7, 139–147 (2007).
  Article CAS Google Scholar